Eli Lilly prepares for FDA rejection of eczema treatment
Following two delays to the FDA’s final decision, Eli Lilly now says that the approval of a new indication in the US might not be in the cards for its eczema drug for adults, Olumiant.
by MIKKEL AABENHUS HEMMINGSEN, translated by daniel pedersen
Eli Lilly’s tug-of-war with the US Food and Drug Administration (FDA) over the treatment for adults with atopic eczema, Olumiant (baricitinib), is currently not looking to end favorably for the US-based pharmaceutical company.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Eli Lilly to build USD 1bn factory in North Carolina
For subscribers
